Bruzzese L, Abbadessa A, Ottaiano L, Arcidiacone G
Haematol Blood Transfus. 1987;30:315-21. doi: 10.1007/978-3-642-71213-5_48.
Seven patients were treated with low dose Ara-C (LDAC). Five patients had acute nonlymphoid leukemia (ANLL), two patients had myelodisplastic syndrome (MDS): refractory anemia (RA) and refractory anemia with excess of blasts in transformation (RAEB-t). Ara-C treatment was given by s.c. injections at a dose of 10-11 mg/m2 every 12 h and only on two occasions by continuous infusion. No improvement, or limited improvement, was observed in five patients and they died of leukemia or of disease-related complications. Two patients with ANLL achieved remission: the first patient after bone marrow aplasia, the second without aplasia but with morphologic evidence of granulocytic differentiation of leukemic cells.
7例患者接受了小剂量阿糖胞苷（LDAC）治疗。5例患者患有急性非淋巴细胞白血病（ANLL），2例患者患有骨髓增生异常综合征（MDS）：难治性贫血（RA）和转化中原始细胞过多的难治性贫血（RAEB-t）。阿糖胞苷治疗采用皮下注射，剂量为每12小时10 - 11mg/m²，仅两次采用持续静脉输注。5例患者未见改善或改善有限，死于白血病或与疾病相关的并发症。2例ANLL患者获得缓解：第一例患者在骨髓再生障碍后缓解，第二例患者未出现再生障碍，但白血病细胞有粒细胞分化的形态学证据。
